Last updated: 14 February 2024 at 8:21pm EST

Yat Sun Or Net Worth




The estimated Net Worth of Yat Sun Or is at least $13.9 Million dollars as of 5 December 2023. Yat Or owns over 2,412 units of Enanta Pharmaceuticals Inc stock worth over $4,463,168 and over the last 11 years he sold ENTA stock worth over $7,827,501. In addition, he makes $1,630,810 as Senior Vice President - Research & Development and Chief Scientific Officer at Enanta Pharmaceuticals Inc.

Yat Or ENTA stock SEC Form 4 insiders trading

Yat has made over 26 trades of the Enanta Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 2,412 units of ENTA stock worth $23,228 on 5 December 2023.

The largest trade he's ever made was exercising 129,087 units of Enanta Pharmaceuticals Inc stock on 3 January 2014 worth over $94,234. On average, Yat trades about 10,753 units every 67 days since 2013. As of 5 December 2023 he still owns at least 370,695 units of Enanta Pharmaceuticals Inc stock.

You can see the complete history of Yat Or stock trades at the bottom of the page.





Yat Sun Or biography

Dr. Yat Sun Or, Ph.D. is Senior Vice President - Research & Development, Chief Scientific Officer of the Company. Prior to joining Enanta, Dr. Or held key leadership positions at Abbott Laboratories from 1985 to 1999, where he received two Chairman’s Awards for his outstanding research, which led to the discovery and development of immunosuppressant and antibacterial drugs. Prior to Abbott, Dr. Or was a member of the cardiovascular drug discovery team at Schering-Plough. Dr. Or received his Ph.D. in Organic Chemistry from the University of Chicago and completed Postdoctoral Fellowships at Ohio State University and Indiana University.

What is the salary of Yat Or?

As the Senior Vice President - Research & Development and Chief Scientific Officer of Enanta Pharmaceuticals Inc, the total compensation of Yat Or at Enanta Pharmaceuticals Inc is $1,630,810. There are 1 executives at Enanta Pharmaceuticals Inc getting paid more, with Jay Luly having the highest compensation of $4,483,500.



How old is Yat Or?

Yat Or is 67, he's been the Senior Vice President - Research & Development and Chief Scientific Officer of Enanta Pharmaceuticals Inc since 1999. There are 2 older and 12 younger executives at Enanta Pharmaceuticals Inc. The oldest executive at Enanta Pharmaceuticals Inc is Bruce Carter, 76, who is the Independent Non-Executive Chairman of the Board.

What's Yat Or's mailing address?

Yat's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.

Insiders trading at Enanta Pharmaceuticals Inc

Over the last 12 years, insiders at Enanta Pharmaceuticals Inc have traded over $72,640,961 worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth $5,071,651 . The most active insiders traders include Jay R. Luly, V Life Science Ventures Gmb..., and Yat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $285,155. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth $190,762.



What does Enanta Pharmaceuticals Inc do?

enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.



What does Enanta Pharmaceuticals Inc's logo look like?

Enanta Pharmaceuticals Inc logo

Complete history of Yat Or stock trades at Enanta Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
5 Dec 2023 Yat Sun Or
Chief Scientific Officer
Sale 2,412 $9.63 $23,228
5 Dec 2023
370,695
15 Mar 2023 Yat Sun Or
Chief Scientific Officer
Option 13,925 $14.00 $194,950
15 Mar 2023
388,627
26 Jan 2021 Yat Sun Or
Chief Scientific Officer
Option 13,693 $12.68 $173,627
26 Jan 2021
330,918
15 Dec 2020 Yat Sun Or
Chief Scientific Officer
Option 5,250 $42.82 $224,805
15 Dec 2020
318,765
16 Dec 2019 Yat Sun Or
Chief Scientific Officer
Option 5,250 $63.88 $335,370
16 Dec 2019
305,923
1 Mar 2019 Yat Sun Or
Chief Scientific Officer
Sale 10,000 $103.53 $1,035,300
1 Mar 2019
300,673
11 Feb 2019 Yat Sun Or
Chief Scientific Officer
Sale 33,981 $89.52 $3,041,979
11 Feb 2019
301,916
4 Jan 2017 Yat Sun Or
Chief Scientific Officer
Sale 13,921 $35.09 $488,488
4 Jan 2017
301,876
29 Nov 2016 Yat Sun Or
Chief Scientific Officer
Sale 13,921 $31.44 $437,676
29 Nov 2016
315,797
19 Jan 2016 Yat Sun Or
Chief Scientific Officer
Option 42,922 $2.54 $109,022
19 Jan 2016
329,718
4 Jan 2016 Yat Sun Or
Chief Scientific Officer
Option 78,565 $2.54 $199,555
4 Jan 2016
286,796
4 Jan 2016 Yat Sun Or
Chief Scientific Officer
Option 78,565 $2.54 $199,555
4 Jan 2016
286,796
10 Aug 2015 Yat Sun Or
Chief Scientific Officer
Sale 3,750 $42.90 $160,875
10 Aug 2015
208,231
13 Jul 2015 Yat Sun Or
Chief Scientific Officer
Sale 3,750 $46.29 $173,588
13 Jul 2015
211,981
11 Jun 2015 Yat Sun Or
Chief Scientific Officer
Sale 3,750 $42.47 $159,263
11 Jun 2015
215,731
5 Jun 2015 Yat Sun Or
Chief Scientific Officer
Sale 10,750 $42.02 $451,715
5 Jun 2015
219,481
11 May 2015 Yat Sun Or
Chief Scientific Officer
Sale 8,000 $36.13 $289,040
11 May 2015
230,231
6 Jan 2015 Yat Sun Or
Chief Scientific Officer
Option 58,004 $1.21 $70,185
6 Jan 2015
238,231
13 Aug 2014 Yat Sun Or
Chief Scientific Officer
Sale 5,000 $39.49 $197,450
13 Aug 2014
180,227
5 Aug 2014 Yat Sun Or
Chief Scientific Officer
Option 11,149 $1.29 $14,382
5 Aug 2014
185,227
1 Jul 2014 Yat Sun Or
Chief Scientific Officer
Sale 5,000 $42.24 $211,200
1 Jul 2014
174,078
2 Jun 2014 Yat Sun Or
Chief Scientific Officer
Sale 5,000 $37.56 $187,800
2 Jun 2014
179,078
1 May 2014 Yat Sun Or
Chief Scientific Officer
Sale 5,000 $36.98 $184,900
1 May 2014
184,078
1 Apr 2014 Yat Sun Or
Chief Scientific Officer
Sale 10,000 $39.16 $391,600
1 Apr 2014
189,078
24 Mar 2014 Yat Sun Or
Chief Scientific Officer
Sale 10,000 $39.34 $393,400
24 Mar 2014
199,078
3 Jan 2014 Yat Sun Or
Chief Scientific Officer
Option 129,087 $0.73 $94,234
3 Jan 2014
209,078


Enanta Pharmaceuticals Inc executives and stock owners

Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include: